Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNK-010 in advanced solid tumors
NCT02040558Phase 1Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jul 2013
- Primary completion
- May 2016
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MNK-010 in solid tumor (advanced stage), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 27 months, Treatment-Emergent Adverse Events at 27 months and 1 more. Started Jul 2013; status: terminated.
02
Drugs
MNK-010
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02040558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040558.